NUREXONE BIOLOGIC INC. Total Assets
NUREXONE BIOLOGIC INC. total assets. Based on the latest financial reports, NUREXONE BIOLOGIC INC. (J90) holds total assets worth €4.08 Million EUR (≈ $4.77 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NUREXONE BIOLOGIC INC. (J90) total market value for the company's overall valuation and market capitalisation.
Total Assets of NUREXONE BIOLOGIC INC. (2021–2025)
Total assets of NUREXONE BIOLOGIC INC. from 2021 to 2025. This chart illustrates how NUREXONE BIOLOGIC INC.'s total assets have evolved over time, based on quarterly financial data. See NUREXONE BIOLOGIC INC. share price for real-time trading data and today's change.
NUREXONE BIOLOGIC INC. - Asset Composition Analysis
NUREXONE BIOLOGIC INC. Total Assets Breakdown (December 2025)
NUREXONE BIOLOGIC INC. total assets breakdown as of December 2025. NUREXONE BIOLOGIC INC.'s total assets of €4.08 Million consist of 63.7% current assets and 36.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 52.4% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how NUREXONE BIOLOGIC INC.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of NUREXONE BIOLOGIC INC. to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NUREXONE BIOLOGIC INC.'s current assets represent 63.7% of total assets in 2025, a decrease from 100.0% in 2021.
- Cash Position: Cash and equivalents constituted 52.4% of total assets in 2025, down from 78.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
NUREXONE BIOLOGIC INC. Competitors by Total Assets
Key competitors of NUREXONE BIOLOGIC INC. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL LTD SPON.ADR 2
F:CSJA
|
Germany | €38.45 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513
|
China | CN¥3.82 Billion |
NUREXONE BIOLOGIC INC. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.63 | 4.11 | 6.49 |
| Quick Ratio | 2.63 | 4.11 | 6.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.61 Million | €1.24 Million | €2.39 Million |
NUREXONE BIOLOGIC INC. - Advanced Valuation Insights
This section examines the relationship between NUREXONE BIOLOGIC INC.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.23 |
| Latest Market Cap to Assets Ratio | 7.54 |
| Asset Growth Rate (YoY) | 67.3% |
| Total Assets | €4.08 Million |
| Market Capitalization | $30.78 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values NUREXONE BIOLOGIC INC.'s assets at a significant premium (7.54x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: NUREXONE BIOLOGIC INC.'s assets grew by 67.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NUREXONE BIOLOGIC INC. (2021–2025)
The table below shows the annual total assets of NUREXONE BIOLOGIC INC. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €4.08 Million ≈ $4.77 Million |
+67.27% |
| 2024-12-31 | €2.44 Million ≈ $2.85 Million |
+12.49% |
| 2023-12-31 | €2.17 Million ≈ $2.54 Million |
-22.33% |
| 2022-12-31 | €2.79 Million ≈ $3.27 Million |
-1.48% |
| 2021-12-31 | €2.84 Million ≈ $3.32 Million |
-- |
About NUREXONE BIOLOGIC INC.
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of p… Read more